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OBJECTIVES The purpose of this study was to determine whether patients with idiopathic dilated
cardiomyopathy (IDCM) exhibit alterations in myocardial fatty acid and glucose metabolism.
BACKGROUND Alterations in myocardial metabolism have been implicated in the pathogenesis of heart
failure (HF); however, studies of myocardial metabolic function in human HF have yielded
conflicting results. Animal models of HF have shown a downregulation of the expression of
enzymes of fatty acid beta-oxidation that recapitulates the fetal energy metabolic program, in
which fatty acid metabolism is decreased and glucose metabolism is increased.
METHODS Seven patients with IDCM (mean left ventricular ejection fraction 27  8%) and 12 normal
controls underwent positron emission tomography for measurements of myocardial blood
flow (MBF), myocardial oxygen consumption (MVO2), myocardial glucose utilization
(MGU), myocardial fatty acid utilization (MFAU) and myocardial fatty acid oxidation
(MFAO).
RESULTS The systolic and diastolic blood pressures, plasma substrates and insulin levels, MBF and
MVO2, were similar between groups. The rates of MFAU and MFAO were significantly
lower in IDCM than in the normal control group (MFAU: 134  44 vs. 213  49
nmol/g/min, p  0.003; and MFAO: 113  50 vs. 205  49 nmol/g/min, p  0.001) and
the rates of MGU were significantly higher in IDCM than the normal control group (MGU:
247  63 vs. 125  64 nmol/g/min, p  0.001).
CONCLUSIONS Patients with IDCM exhibit alterations in myocardial metabolism characterized by decreased
fatty acid metabolism and increased myocardial glucose metabolism, a pattern similar to that
shown in animal models of HF. Whether alterations in myocardial metabolism constitute an
adaptive response or mediate the development of HF remains to be determined. (J Am Coll
Cardiol 2002;40:271–7) © 2002 by the American College of Cardiology Foundation
Alterations in myocardial substrate metabolism have been
implicated in the pathogenesis of contractile dysfunction
and heart failure (HF) (1–3). Animal models of HF have
shown that in the progression from cardiac hypertrophy to
ventricular dysfunction, the expression of genes encoding
for mitochondrial fatty acid beta-oxidation (FAO) enzymes
is coordinately decreased, resulting in a shift in myocardial
metabolism that recapitulates the fetal heart gene program,
with glucose instead of fatty acids becoming the primary
energy substrate (4–8).
The reactivation of the metabolic fetal gene program may
have detrimental consequences on myocardial contractile
function. The downregulation of mitochondrial FAO en-
zymes is associated with increased myocardial utilization of
oxygen-sparing glycolytic pathways for the production of
high-energy phosphates (4). Although this allows for re-
duced oxygen demands in the hypertrophied and failing
heart, the reliance of the myocardium on glucose may
produce a relatively energy-deficient state that over a long
time may result in decreased contractile performance (1–3).
Alternatively, the inability to metabolize fatty acids in the
presence of excess availability may be associated with accu-
mulation of nonoxidized toxic fatty acid derivatives, result-
ing in lipotoxicity and HF (9). This hypothesis is supported
by the development of myocardial hypertrophy, HF and
sudden cardiac death in children with genetic defects in
myocardial FAO enzymes (10–12). Furthermore, myocar-
dial FAO enzyme expression is downregulated in humans
with dilated cardiomyopathy, suggesting that a gene regu-
latory program is responsible for the alterations in myocar-
dial energy substrate utilization (13).
Animal studies have provided significant insight into the
metabolic alterations that occur in HF; however, studies in
humans have yielded conflicting results. Accordingly, we
measured myocardial fatty acid and glucose metabolism by
positron emission tomography (PET) in patients with
idiopathic dilated cardiomyopathy (IDCM) and compared
these values with those obtained in normal controls. The
hypothesis of this study was that patients with IDCM
exhibit alterations in myocardial metabolism that are similar
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to those shown in animal models of HF, manifested by
reduced levels of myocardial fatty acid utilization (MFAU)
and myocardial fatty acid oxidation (MFAO) and by in-
creased levels of myocardial glucose utilization (MGU).
METHODS
Study population. The study population consisted of pa-
tients with IDCM and normal controls. Inclusion criteria
for patients with IDCM were: 1) diagnosis of cardiomyop-
athy within 18 months of enrollment; 2) no evidence of
coronary artery disease (CAD) as assessed by coronary
angiography; and 3) global moderate-to-severe left ventric-
ular dysfunction (global hypokinesis). Normal controls were
recruited by advertisement and had no history or symptoms
of cardiovascular disease. All patients and normal controls
underwent a complete cardiac evaluation, including a his-
tory, physical exam and echocardiogram.
Exclusion criteria for both IDCM patients and normal
controls were: 1) causes of cardiomyopathy (other than
IDCM for the patients), such as valvular, restrictive or
hypertrophic, or due to sarcoidosis, amyloidosis, hemochro-
matosis, pericardial and/or congenital heart disease; 2)
diabetes mellitus or other systemic disease (malignancy,
collagen vascular disease); 3) smoker; 4) previous cardiac
surgery; 5) age 20 or 80 years; 6) elevated serum
creatinine (2.5 mg/dl); 7) pregnancy; and 8) treatment
with beta-blockers (to avoid the confounding effects of this
drug on myocardial contractile and metabolic function).
Patients were treated with standard individualized ther-
apy for HF, including angiotensin-converting enzyme in-
hibitors, angiotensin receptor blockers, diuretics, digoxin
and nitrates. After completing the imaging protocol, pa-
tients were considered for treatment with beta-blockers. All
patients had been clinically stable for at least one month
before completing the study protocol. Written informed
consent, approved by the Human Studies Committee and
the Radioactive Drug Research Committee at Washington
University School of Medicine, was obtained from all study
subjects.
Imaging protocol. ECHOCARDIOGRAPHY. All patients and
normal controls underwent complete two-dimensional and
Doppler echocardiography to determine the left ventricular
ejection fraction (LVEF) and left ventricular mass index and
to assess valve function (14). Normal controls also under-
went exercise stress echocardiography to assess for CAD;
those with an ischemic response (chest pain, electrocardio-
gram and/or echocardiographic ischemia) were excluded.
CARDIAC PET. All studies were performed on conventional
commercially available tomographs (Siemens ECAT 962
HR, Siemens Medical Systems, Iselin, New Jersey). After
a 12-h overnight fast, all subjects underwent a PET imaging
protocol (Fig. 1) to measure myocardial blood flow (MBF),
myocardial oxygen consumption (MVO2), MFAU and
MFAO, and MGU. A transmission scan was performed to
correct for photon attenuation used in emission-image
reconstruction. To measure MBF, an intravenous bolus of
0.40 mCi/kg (up to 25 mCi) of 15O-water was followed by
5-min dynamic data collection. To measure MVO2, an
intravenous bolus of 0.40 mCi/kg of 11C-acetate was given
followed by a 30-min dynamic data collection. To measure
MGU, an intravenous bolus of 0.40 mCi/Kg of 11C-glucose
was given followed by a 60-min dynamic data collection.
MFAU and MFAO were measured using an intravenous
bolus of 0.40 mCi/kg of 11C-palmitate, followed by a
30-min dynamic data collection. During the 11C-acetate,
11C-glucose and 11C-palmitate data collections, venous
blood samples were obtained at predetermined intervals to
measure plasma substrates (such as glucose and free fatty
acids) and plasma 11CO2 values and
11C-lactate (in the case
of 11C-glucose) to correct the arterial input function for
compartmental modeling of the myocardial kinetics of the
various metabolic tracers. Heart rate and blood pressure
were monitored continuously throughout the study, which
was completed in approximately 6 h.
Image analysis. All PET-derived images were reoriented
to generate standard short- and long-axis views. Myocardial
time-activity curves were generated by placing a region of
Abbreviations and Acronyms
CAD  coronary artery disease
FAO  fatty acid oxidation
HF  heart failure
IDCM  idiopathic dilated cardiomyopathy
LVEF  left ventricular ejection fraction
MBF  myocardial blood flow
MFAO  myocardial fatty acid oxidation
MFAU  myocardial fatty acid utilization
MGU  myocardial glucose utilization
MVO2  myocardial oxygen consumption
NYHA  New York Heart Association
PET  positron emission tomography
Figure 1. Positron emission tomography (PET) imaging protocol to assess
myocardial metabolism. After a 12-h overnight fast, all subjects underwent
a PET imaging protocol (starting at 8:00 AM) to measure myocardial blood
flow; myocardial oxygen consumption; myocardial glucose uptake and
utilization; and myocardial fatty acid uptake, utilization, and oxidation.
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interest on three to four mid-ventricular short-axis slices on
the anterolateral wall (3 to 5 cm3) of composite 15O-water,
11C-acetate, 11C-glucose and 11C-palmitate images as pre-
viously described (15–19). To generate blood time-activity
curves for each tracer, a small region of interest (1 cm3) was
placed within the left atrial cavity on a mid-ventricular slice
in the vertical long-axis orientation of each composite
image. Within these regions of interest, myocardial and
blood time-activity curves were generated for 15O-water,
11C-acetate, 11C-glucose and 11C-palmitate, respectively.
To avoid contamination from right ventricular blood and
liver radioactivity, septal and inferior regions were omitted.
Subsequently, blood and myocardial time-activity curves
were used in conjunction with well-established kinetic
models to measure MBF (ml/g/min), MVO2, MFAU,
MFAO and MGU (all in nmol/g/min) in each myocardial
region analyzed and averaged to obtain one value of each per
subject. Correction for partial volume effects was imple-
mented in the 15O-water kinetic model. The partial volume
correction factor obtained from the 15O-water kinetic
model was subsequently used in the kinetic modeling for all
the other PET-derived measurements (MVO2, MFAU,
MFAO and MGU). Blood-to-myocardium count spillover
was accounted for in each of the models by estimating the
spillover fraction along with the model transfer-rate con-
stants.
MEASUREMENT OF MBF. By applying the image-analysis
routine to the time-segmented data, we generated myocar-
dial time-activity curves for each segment. From these data,
MBF was quantified using a compartmental modeling
approach previously validated (15–19).
MEASUREMENT OF MVO2 After we corrected PET-derived
blood activity for 11CO2 contribution, blood and myocardial
time-activity curves were used in conjunction with a one-
compartment kinetic model to estimate the rate at which
11C-acetate is converted to 11CO2 (k2, min
1). Values for
MVO2 were determined using a known relationship be-
tween k2 and MVO2 (16,17).
MEASUREMENT OF MFAU, MFAO AND MGU. After correcting
the PET-derived blood 11CO2 activity, blood and myocar-
dial 11C-palmitate time-activity curves were used in con-
junction with a four-compartment kinetic model to measure
fractional myocardial palmitate extraction and oxidation
(18). In a similar fashion, after correcting PET-derived
blood activity for the key metabolites of 11C-glucose (11CO2
and 11C-lactate), blood and myocardial 11C-glucose time-
activity curves were used in conjunction with a four-
compartment kinetic model to measure fractional myocar-
dial glucose extraction (19).
Substrate uptake (in ml/g/min) is the product of the
substrate extraction fraction and MBF (Equation 1). Sub-
strate uptake thus represents the rate at which the substrate
is taken up by the myocardium, and is independent of the
level of substrate in plasma. Substrate utilization (in nmol/
g/min) is the product of substrate uptake and the concen-
tration of substrate in plasma (Equation 2) and thus reflects
the amount of substrate taken up by myocardium. Changes
in substrate utilization may be due to changes in extraction
fraction, MBF and/or plasma substrate levels.
The tracer extraction fractions are used in conjunction
with MBF and plasma levels of free fatty acid or glucose to
calculate the total tracer uptake and utilization (MGU and
MFAU).
Myocardial tracer uptake ml/g/min 
MBF  tracer extraction fraction [1]
Myocardial substrate utilization nmol/g/min 
myocardial tracer uptake  substrate plasma level [2]
Myocardial FAO was measured from the kinetics of
11C-palmitate by calculating from the model transfer-rate
constants the portion of total tracer extraction that is
converted to 11CO2 (fast-turnover pool) and is assumed to
be oxidized. This fractional oxidation was then used in
Equations 1 and 2 to measure MFAO.
Statistical analysis. Results for each parameter were aver-
aged and expressed as the mean values  SD. Comparisons
between groups were performed by unpaired t test; p values
0.05 were considered statistically significant.
RESULTS
Patient characteristics. Seven patients with IDCM (3
women, mean age 39  7 years) and 12 normal controls (9
women, mean age 26 5 years) were enrolled into the study
(Table 1). At the time of the initial referral to the HF clinic,
all patients were in New York Heart Association (NYHA)
functional class IV. However, at the time of enrollment into
this study, patients were in stable HF: three were in NYHA
functional class II and four were in NYHA functional class
III. The mean duration of HF for the group was 15 months.
Two patients had a history of hypertension, two had a
history of hyperlipidemia; none had diabetes mellitus. As
expected, patients with IDCM had significantly lower
Table 1. Characteristics of IDCM Patients and
Normal Controls
Normal
Controls
(n  12)
IDCM
(n  7) p Value
Age (yrs) 26  5 39  7 0.0002
BMI (kg/m2) 25  6 31  7 0.10
LVEF (%) 63  8 27  8 0.001
LVMI (g/m2) 71  10 110  23 0.001
HR (beats/min) 64  12 82  17 0.02
SBP (mm Hg) 109  12 114  23 0.52
DBP (mm Hg) 63  7 68  17 0.39
RPP (mm Hg  beats  min1) 5116  1431 6926  2327 0.05
BMI  body mass index; DBP  diastolic blood pressure; HR  heart rate;
IDCM  idiopathic dilated cardiomyopathy; LVEF  left ventricular ejection
fraction; LVMI  left ventricular mass index; RPP  rate-pressure product; SBP 
systolic blood pressure.
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LVEF and significantly higher left ventricular mass com-
pared with the normal control group.
Cardiac imaging studies. REST HEMODYNAMICS, PLASMA
SUBSTRATES AND INSULIN LEVELS, MBF AND MVO2. The
heart rate and the rate-pressure product were significantly
higher in the IDCM group compared with the normal
control group; however, the systolic and diastolic blood
pressures were similar for both groups (Table 1). Plasma
levels of fatty acids, glucose, and insulin, and measurements
of MBF and MVO2 were similar for both groups (Table 2).
MYOCARDIAL FATTY ACID AND GLUCOSE METABO-
LISM. Myocardial substrate uptake was significantly differ-
ent between the two groups: FFA uptake was lower and
glucose uptake was higher in the IDCM group (Table 2).
Rates of myocardial fatty acid metabolism were significantly
lower in the IDCM group compared with the normal
control group (MFAU: 134 44 vs. 213 49 nmol/g/min,
p  0.003; MFAO: 113  50 vs. 205  49 nmol/g/min, p
 0.001, respectively, Fig. 2). Rates of MGU were signif-
icantly higher in the IDCM group compared with the
normal control group (247  63 vs. 125  64 nmol/g/min,
p  0.001, respectively, Fig. 2). Thus, patients with IDCM
exhibit reduced rates of myocardial fatty acid metabolism
and increased rates of myocardial glucose metabolism com-
pared with normal subjects. Moreover, these differences
could not be attributed to differences in plasma substrate
levels or differences in myocardial uptake of fatty acids or
glucose, because these values paralleled those for MFAU,
MFAO and MGU in both groups (Table 2).
DISCUSSION
Results of this study demonstrate that patients with IDCM
exhibit a shift in myocardial substrate metabolism mani-
fested by increased rates of myocardial glucose uptake and
utilization and decreased rates of myocardial fatty acid
uptake and MFAU that is paralleled by a decrease in
MFAO. These changes cannot be explained by differences
in plasma substrates, insulin, MBF or MVO2. Downregu-
lated expression of myocardial genes involved in mitochon-
drial FAO has been shown in animals with pressure-
overload cardiac hypertrophy, in animals with HF and in
pathologic specimens of humans with dilated cardiomyop-
athy (1,4,13). As previously shown in animal models of HF,
in this study we show, in vivo, that alterations in myocardial
energy metabolism also occur in humans with IDCM.
Taken together, the animal and human studies show that
alterations in myocardial fatty acid and glucose metabolism
occur in HF. Whether these alterations represent an adap-
tive response of the failing heart or whether they play a
Table 2. Plasma Substrates and Insulin, MBF, MVO2, and
Myocardial Substrate Uptake
Plasma Substrates
Normal
Controls
(n  12)
IDCM
(n  7) p Value
Glucose (mol/ml) 4.9  0.4 5.0  0.3 0.39
Insulin (U/ml) 5.1  3.6 5.2  7.8 0.94
FFA (nmol/ml) 665  174 597  157 0.41
MBF (ml/g/min) 1.0  0.2 0.9  0.2 0.21
MVO2 (nmol/g/min) 4934  830 4935  770 0.99
Myocardial FFA uptake
(l/g/min)
330  80 236  33 0.01
Myocardial glucose uptake
(l/g/min)
26  14 49  13 0.003
FFA  free fatty acids; IDCM  idiopathic dilated cardiomyopathy; MBF 
myocardial blood flow; MVO2  myocardial oxygen consumption.
Figure 2. Myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy (IDCM). Patients with IDCM exhibited significantly lower
rates of myocardial fatty acid utilization and myocardial fatty acid oxidation and significantly higher rates of myocardial glucose utilization compared with
normal subjects.
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pathophysiologic role remains to be determined. If these
alterations represent a maladaptive response, novel treat-
ment strategies in HF may involve metabolic manipulation.
Myocardial metabolism in the normal and failing heart.
During the fetal stages of the developing mammalian heart,
glucose is the primary energy substrate for energy produc-
tion, while FAO rates are very low (5,20–21). Shortly after
birth and in the normal adult heart, a fall in plasma insulin
levels, coupled with decreased availability of glucose and
increased availability of fatty acids, leads to enzymatic
changes, including increased expression of mitochondrial
FAO enzymes that result in a parallel increase in the
production of adenosine triphosphate from myocardial
FAO (5). Thus, in the normal adult myocardium, mito-
chondrial FAO is the primary source of intracellular energy.
Animal studies have shown that myocardial energy sub-
strate utilization is altered in association with the develop-
ment of pathologic forms of ventricular hypertrophy and in
the failing heart: fatty acid utilization decreases while
glycolysis increases (1,4,22–25). Recent studies have shown
that along with the re-expression of fetal isoforms of a
variety of contractile and calcium regulatory proteins, the
switch from myocardial FAO to glycolysis during the
development of pressure-overload LVH and HF recapitu-
lates the fetal heart phenotype (4,13).
Activation of the fetal gene program may initially be an
adaptive structural and metabolic response of the overloaded
ventricle to maximize efficiency and decrease oxygen con-
sumption. This is supported by the known severe clinical
manifestations resulting from genetic defects of myocardial
FAO enzymes, including cardiomyopathy and sudden car-
diac death (10–12). In the genetic form of metabolic
cardiomyopathy, HF often ensues during acute illness asso-
ciated with fasting, when glucose (the principal substrate) is
not readily available. In these patients, the diminished rate
of FAO and consequent increased reliance on glucose
oxidation that is characteristic of this condition occurs in a
pattern similar to that exhibited by the IDCM patients in
the present study. Thus, the hypothesis is that defective
myocardial FAO leads to inadequate energy production,
particularly under conditions of increased work, a phenom-
enon that has been referred to as decreased energy reserve
(2). Furthermore, the accumulation of nonoxidized fatty
acid derivatives in the myocardium may lead to lipotoxicity
and HF (9). Accumulation of long-chain carnitine esters
has been shown to cause ventricular arrhythmias, particu-
larly under conditions of myocardial ischemia, implying that
these metabolic derangements may also play a role in sudden
cardiac death associated with ventricular hypertrophy and
with cardiomyopathy (12,26,27).
Comparison of this study with previous studies of myo-
cardial metabolic function in HF. Numerous studies of
patients with cardiomyopathy have yielded conflicting re-
sults (28–34). Early studies of myocardial metabolism
assessed patients with HF by using PET to estimate the
clearance rates of long-chain fatty acids tracers such as
11C-palmitate (35–38). The initial uptake of 11C-palmitate
represents primarily MBF; it then clears the myocardium in
a bi-exponential pattern, with the early rapid phase reflect-
ing FAO and the slow clearance representing incorporation
of the tracer into the lipid pool. By use of this method,
decreased rates of MFAO were shown in patients with
myocardial long-chain acyl-CoA dehydrogenase genetic
defects (38). Furthermore, the extent of decreased clearance
of 11C-palmitate was shown to correlate with the clinical
severity.
Our group has recently validated the use of 11C-palmitate
and 11C-glucose for the quantification of fatty acid and
glucose metabolism, respectively, determined by compart-
mental modeling, a more accurate and robust technique
than estimation of clearance rates (18,19). The present
study was conducted using compartmental modeling to
determine myocardial metabolism.
A study using iodine-123 beta-methyl-iodophenyl pen-
tadecanoic acid (a fatty acid analogue whose uptake parallels
that of palmitate but is resistant to FAO) also showed
impaired myocardial fatty acid uptake in patients with
IDCM (34). Despite the limitations of this study (no
attenuation or scatter correction, inability to quantify de-
fects, use of a fatty acid analogue that does not undergo
FAO) and despite the uncertain significance of their iodine-
123 beta-methyl-iodophenyl pentadecanoic acid–thallium-
201 mismatch (supposedly all patients had normal coronar-
ies), our study confirms their findings. Furthermore, the
present study shows additional findings that further confirm
altered myocardial metabolism in IDCM, such as decreased
MFAU and MFAO, paralleled by increased MGU.
Others have used (18F)fluoro-6-thia-heptadecanoic acid
(a long-chain fatty acid analogue) and 18F-fluorodeoxy-
glucose (a glucose analogue) to show that patients with HF
exhibit increased rates of myocardial fatty acid uptake and
lower rates of myocardial glucose uptake (31–33). These
findings are discrepant from those of our study, and several
differences between these two studies may explain these
discrepancies. First, the previous study included a hetero-
geneous study population composed of patients with both
ischemic and nonischemic cardiomyopathy; our study in-
cluded only patients with nonischemic cardiomyopathy.
Second, a control population was not included in the
previous study; our study included a normal control group.
Third, the previous study used tracer analogues of both fatty
acids and glucose. Tracer analogues afford only an indirect
assessment of substrate metabolism because they are metab-
olized differently from the metabolite being studied. Our
study used metabolic tracers of the actual substrates being
evaluated (palmitate and glucose). Fourth, contrary to our
study, the previous study did not assess plasma substrate
levels, MBF or MVO2 levels, all of which influence myo-
cardial substrate uptake and myocardial metabolism. Fi-
nally, the results of the previous studies are in contradiction
with the large scientific literature, ranging from cellular
preparations to animal models of HF, and even studies of
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explanted hearts of humans with cardiomyopathy that show
downregulation of fatty acid metabolism and upregulation
of glucose metabolism.
Study limitations. The goal of the present study was to
show alterations in myocardial metabolism in a homoge-
neous group of patients with IDCM. This particular patient
population was chosen to avoid the limitations of previous
studies that included a heterogeneous study population.
Specifically, we wanted to avoid the confounding effects that
CAD, ischemic cardiomyopathy and treatment with beta-
blockers have on the segmental and global measurements of
MBF, MVO2, and contractile and metabolic function.
Although the rigorous study entry criteria limited the
number of eligible patients, this group was very homoge-
neous and representative of patients with IDCM. Further-
more, the differences found between IDCM and normal
controls were quite striking and are in agreement with those
previously documented in animal models of HF, in humans
with IDCM, and in humans with genetic defects of fatty
acid metabolism.
The patients with IDCM were older than the normal
controls. However, both groups were relatively young adults
and thus their age difference is not large enough to account
for the dramatic alterations in myocardial metabolism ob-
served between these groups.
Clinical implications of the results of this study. The
precise mechanisms leading to HF have not been well
characterized. Although there is no conclusive evidence
directly implicating metabolic abnormalities in the patho-
physiology of HF in humans, there is strong scientific
evidence, based on animal models, that this is one of several
possible mechanisms. Thus, the present study shows, in
agreement to what has been previously identified in animal
models of HF, that myocardial fatty acid and glucose
metabolism are altered in HF, suggesting that at least in
human IDCM, the phenotypic manifestations match the
genotypic expression seen in animal models. By use of
PET-derived techniques, it is now possible to study nonin-
vasively, in vivo, in humans, the metabolic alterations that
occur in association with the transition from ventricular
hypertrophy to HF. Furthermore, patients that exhibit these
metabolic abnormalities can now be identified and poten-
tially risk-stratified based on the severity of these abnormal-
ities. Finally, this noninvasive PET-derived approach may
allow identification of patients with HF whose metabolic
abnormalities may be a target for metabolic modulation.
One such potential target is peroxisome proliferator-
activated receptor alpha, a nuclear receptor known to
control the expression of myocardial FAO enzymes (39).
Conclusions. The precise mechanisms mediating reduced
myocardial contractile performance and resulting in HF
have not been well characterized. In this study, we show that
patients with IDCM exhibit alterations in myocardial me-
tabolism characterized by decreased MFAU and MFAO
and by increased MGU. These findings are in agreement
with those previously identified in animal models of HF, in
pathologic specimens of humans with dilated cardiomyop-
athy and in humans with genetic defects of fatty acid
metabolism, that myocardial fatty acid and glucose metab-
olism is altered in HF. Whether alterations in myocardial
metabolism are an adaptive response or mediate the devel-
opment of HF remains to be determined.
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